RT Journal Article
SR Electronic
T1 Induction Chemotherapy with Docetaxel, Cisplatin and Fluorouracil Followed by Surgery and Concurrent Chemoradiotherapy Improves Outcome of Recurrent Advanced Head and Neck Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3765
OP 3773
VO 34
IS 7
A1 WEN-CHI YANG
A1 CHUNG-HO CHEN
A1 JEN-YANG TANG
A1 CHIH-FUNG WU
A1 YI-CHANG LIU
A1 YOUPING SUN
A1 SHENG-FUNG LIN
YR 2014
UL http://ar.iiarjournals.org/content/34/7/3765.abstract
AB Background: Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial. Patients and Methods: We retrospectively analyzed ninety-three patients with recurrent advanced oral cancer from 2009 to 2013. Sixty-four patients are in the docetaxel with cisplatin and 5’-fluorouracil (TPF) group and the remaining twenty-nine patients are in the cisplatin and 5’-fluorouracil (PF) group. Results: The overall response rate was better in the TPF group (p=0.005) than the PF group. Patients who received induction chemotherapy, TPF, followed by surgery and concurrent chemoradiotherapy (CRT) had better overall survival (OS) (p=0.012) and progression-free survival (PFS) (p=0.038), while patients with prior intra-arterial-infusion-chemotherapy had an adverse impact on OS (p=0.039). Conclusion: We showed that induction chemotherapy with TPF, followed by surgery and consolidation CRT, is the ideal choice for recurrent advanced HNSCC with improving response rates and survival. However, prior intra-arterial-infusion-chemotherapy showed an adverse impact.